M2951

DRUG3 trials

Sponsors

EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions

HealthyRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants

CompletedNCT04697511

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2021-01-11End: 2021-02-25Updated: 2021-03-23

Phase 2

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

CompletedNCT02784106

EMD Serono Research & Development Institute, Inc.Rheumatoid Arthritis

Start: 2016-07-31End: 2017-11-14Updated: 2018-07-17

A Phase II Study of M2951 in SLE

TerminatedNCT02975336

EMD Serono Research & Development Institute, Inc.Systemic Lupus Erythematosus

Start: 2017-01-04End: 2020-03-23Updated: 2021-04-12

Related Papers

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

Multiple Sclerosis Journal2023-08-254 citations

A Plain Language Summary of What Clinical Studies Can Tell Us About the Safety of Evobrutinib – a Potential Treatment for Multiple Sclerosis

Neurodegenerative Disease Management2023-06-223 citations

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Journal of Neurology Neurosurgery & Psychiatry2022-11-2329 citations

212 Phase 2, randomized, double-blind, placebo-controlled, dose-finding study, evaluating the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with systemic lupus erythematosus: study design

Abstracts2019-04-012 citations